Abstract
In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 674-675 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 116 |
| Issue number | 5 |
| DOIs |
|
| State | Published - Aug 5 2010 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology